Navigation Links
Nearly a century later, new findings support Warburg theory of cancer
Date:1/11/2009

CHESTNUT HILL, MA (January 12, 2009) German scientist Otto H. Warburg's theory on the origin of cancer earned him the Nobel Prize in 1931, but the biochemical basis for his theory remained elusive.

His theory that cancer starts from irreversible injury to cellular respiration eventually fell out of favor amid research pointing to genomic mutations as the cause of uncontrolled cell growth.

Seventy-eight years after Warburg received science's highest honor, researchers from Boston College and Washington University School of Medicine report new evidence in support of the original Warburg Theory of Cancer.

A descendant of German aristocrats, World War I cavalry officer and pioneering biochemist, Warburg first proposed in 1924 that the prime cause of cancer was injury to a cell caused by impairment to a cell's power plant or energy metabolism found in its mitochondria.

In contrast to healthy cells, which generate energy by the oxidative breakdown of a simple acid within the mitochondria, tumors and cancer cells generate energy through the non-oxidative breakdown of glucose, a process called glycolysis. Indeed, glycolysis is the biochemical hallmark of most, if not all, types of cancers. Because of this difference between healthy cells and cancer cells, Warburg argued, cancer should be interpreted as a type of mitochondrial disease.

In the years that followed, Warburg's theory inspired controversy and debate as researchers instead found that genetic mutations within cells caused malignant transformation and uncontrolled cell growth. Many researchers argued Warburg's findings really identified the effects, and not the causes, of cancer since no mitochondrial defects could be found that were consistently associated with malignant transformation in cancers.

Boston College biologists and colleagues at Washington University School of Medicine found new evidence to support Warburg's theory by examining mitochondrial lipids in a diverse group of mouse brain tumors, specifically a complex lipid known as cardiolipin (CL). They reported their findings in the December edition of the Journal of Lipid Research.

Abnormalities in cardiolipin can impair mitochondrial function and energy production. Boston College doctoral student Michael Kiebish and Professors Thomas N. Seyfried and Jeffrey Chuang compared the cardiolipin content in normal mouse brain mitochondria with CL content in several types of brain tumors taken from mice. Bioinformatic models were used to compare the lipid characteristics of the normal and the tumor mitochondria samples. Major abnormalities in cardiolipin content or composition were present in all types of tumors and closely associated with significant reductions in energy-generating activities.

The findings were consistent with the pivotal role of cardiolipin in maintaining the structural integrity of a cell's inner mitochondrial membrane, responsible for energy production. The results suggest that cardiolipin abnormalities "can underlie the irreversible respiratory injury in tumors and link mitochondrial lipid defects to the Warburg theory of cancer," according to the co-authors.

These findings can provide insight into new cancer therapies that could exploit the bioenergetic defects of tumor cells without harming normal body cells.


'/>"/>

Contact: Ed Hayward
ed.hayward@bc.edu
617-552-4826
Boston College
Source:Eurekalert  

Related biology news :

1. Restless legs syndrome affects nearly 2 percent of US/UK children
2. Yam bean a nearly forgotten crop
3. NIH awards nearly $23M to University of Chicago for translational research
4. Yam bean a nearly forgotten crop
5. UCR researchers awarded nearly $1.7M to develop improved cowpea varieties
6. Gaining too much weight during pregnancy nearly doubles risk of having a heavy baby
7. Joslin research finds nearly three-quarters of youths with diabetes insufficient in vitamin D
8. 21st-century pack mule: MITs exoskeleton lightens the load
9. St. Jude settles century-old debate on origin of mammalian network of lymphatic vessels
10. Carnivores in recent study help Bergmanns rule reach the 21st century
11. Building the future -- 21st century nano tools to repair the nervous system
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Nearly a century later, new findings support Warburg theory of cancer
(Date:1/3/2017)... VEGAS , Jan. 3, 2017 Onitor, ... the introduction of Onitor Track, an innovative biometric data-driven ... men, showcasing this month at the 2017 Consumer Electronics ... In the U.S., the World Health ... more than two-thirds of adults who are overweight or ...
(Date:12/20/2016)... 20, 2016   Valencell , the leading ... STMicroelectronics (NYSE: STM), a global semiconductor leader ... announced today the launch of a new, highly ... that includes ST,s compact SensorTile turnkey ... biometric sensor system. Together, SensorTile and Benchmark deliver ...
(Date:12/16/2016)... The global wearable medical device market, in terms of ... USD 5.31 billion in 2016, at a CAGR of 18.0% during ... ... in medical devices, launch of a growing number of smartphone-based healthcare ... healthcare providers, and increasing focus on physical fitness. ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... and GAITHERSBURG, Md. , Jan. ... and Altimmune, Inc., a privately-held immunotherapeutics company targeting ... definitive agreement for the merger of PharmAthene and ... include Novartis Venture Fund, HealthCap, Truffle Capital and ... fully-integrated and diversified immunotherapeutics company with four clinical ...
(Date:1/19/2017)... ... 2017 , ... FireflySci Inc. is a go-getter type of company that continues ... to two main factors. The first is the amazing customer service that the ... products all around the world. , 2016 was a tremendous sales year for FFS ...
(Date:1/19/2017)... FRANKLIN LAKES, N.J. , Jan. 18, 2017 BD ... medical technology company, announced today that it will host a live ... 2017, at 1 p.m. (ET). The webcast can ... will be available for replay through Tuesday, January 31, 2017. ... About BD ...
(Date:1/18/2017)... --  Parent Project Muscular Dystrophy (PPMD) , a nonprofit ... dystrophy (Duchenne) , today announced a $600,000 grant to ... (NJIT) and Talem Technologies (Talem) as part of the ... assist people living with Duchenne. PPMD is funding a ... computer, software, a force sensor and a motor – ...
Breaking Biology Technology: